UPDATE: BMO Capital Starts Pfizer (PFE) at Outperform

Cardiff Oncology (CRDF) Announces $15M Equity Investment from Pfizer (PFE); Pfizer Acquires 2.4M Share at $6.22/sh

November 18, 2021 7:02 AM EST

(Updated - November 18, 2021 7:03 AM EST)

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need (including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer), today announced that Pfizer Inc. (NYSE: PFE) has made a $15 million equity investment in the company as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative... More

Pfizer (PFE) Announces Agreement to Supply 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to US Govt

November 18, 2021 6:45 AM EST

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID (PF-07321332; ritonavir), subject to regulatory authorization from the U.S. Food and Drug Administration (FDA). If approved or authorized, PAXLOVID, which originated in Pfizers... More

Pfizer CFO D'Amelio to retire after 15 years at company

November 17, 2021 6:54 AM EST

(Reuters) - Pfizer Inc said on Wednesday Chief Financial Officer Frank D'Amelio, 63, would retire after nearly 15 years at the company.

The drugmaker has started an external search for the successor of D'Amelio, who also served as executive vice president of global supply.

During his tenure, Pfizer slimmed... More

Pfizer (PFE) Announces CFO Retirement

November 17, 2021 6:46 AM EST

Pfizer Inc. (NYSE: PFE) today announced that Frank DAmelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer after a nearly 15 year distinguished career with the Company. Pfizer has initiated an external search for a new Chief Financial Officer and DAmelio has agreed to stay on board through this process and serve in a consulting role through the transition. With DAmelios planned departure, and his significant contributions to Pfizers manufacturing capabilities, the Company has made the decision to name Mike McDermott, Executive... More

FDA plans to authorize Pfizer (PFE) - BioNTech (BNTX) boosters as soon as Thursday - NYT

November 16, 2021 5:20 PM EST

FDA plans to authorize Pfizer (NYSE: PFE) - BioNTech (NASDAQ: BNTX) boosters as soon as Thursday - NYT

... More

Pfizer files for U.S. authorization of promising COVID-19 antiviral pill

November 16, 2021 2:10 PM EST

By Michael Erman

(Reuters) - Pfizer Inc said on Tuesday it is seeking U.S. authorization of its experimental antiviral COVID-19 pill that cut the chance of hospitalization or death for adults at risk of severe disease by 89% in a clinical trial.

Pfizer said it completed submission of its application for emergency use authorization (EUA) of the drug, Paxlovid, with the U.S. Food and Drug Administration, including data from the drugmaker's clinical trial.

The oral drug could be a promising new weapon in the fight against the... More

Pfizer (PFE) Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate

November 16, 2021 2:00 PM EST

Pfizer Inc. today announced it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID (PF-07321332; ritonavir), for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalizations or death. This submission to the U.S. Food and Drug Administration (FDA) includes clinical data from the Phase 2/3 EPIC-HR... More

White House to buy 10M courses of Pfizer (NYSE: PFE) COVID Pill - WaPo

November 16, 2021 1:24 PM EST

White House to buy 10M courses of Pfizer (NYSE: PFE) COVID Pill - WaPo

... More

Pfizer to allow generic versions of its COVID pill in 95 countries

November 16, 2021 6:48 AM EST

By Michael Erman and Emma Farge

(Reuters) -Pfizer Inc said on Tuesday it will allow generic manufacturers to supply its experimental antiviral COVID-19 pill to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP).

The voluntary licensing agreement between Pfizer and the MPP will allow the UN-backed group to grant sub-licences to qualified generic drug manufacturers to make their own versions of PF-07321332. Pfizer will sell the pills it manufactures under the brand name Paxlovid.

Medical charity Medecins Sans Frontieres said it was "disheartened" by the deal which... More

Pfizer (PFE) Announces Licensing Agreement with Medicines Patent Pool (MPP) for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries

November 16, 2021 6:46 AM EST

Pfizer Inc. (NYSE: PFE) and the Medicines Patent Pool (MPP), a United Nations-backed public health organization working to increase access to life-saving medicines for low- and middle-income countries, today announced the signing of a voluntary license agreement for Pfizers COVID-19 oral antiviral treatment candidate PF-07321332, which is administered in combination with low dose ritonavir (PF-07321332; ritonavir). The... More

Pfizer (PFE) Agrees To Allow Cheaper Versions Of Its Covid-19 Pill - Bloomberg

November 16, 2021 6:45 AM EST

Pfizer (NYSE: PFE) Agrees To Allow Cheaper Versions Of Its Covid-19 Pill - Bloomberg

... More